Type 1 diabetes TrialNet - An international collaborative clinical trials network

Annals of the New York Academy of Sciences

Volumn 1150, Issue , 2008, Pages 14-24

  Skyler, Jay S ^a,b   Greenbaum, Carla J ^a   Lachin, John M ^a   Leschek, Ellen ^a   Rafkin Mervis, Lisa ^a   Savage, Peter ^a   Spain, Lisa ^a  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Immunomodulation; Network; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; CD3 ANTIBODY; DACLIZUMAB; EXENDIN 4; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

CELL PROLIFERATION; CELL REGENERATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL COOPERATION; ORAL GLUCOSE TOLERANCE TEST; OUTCOMES RESEARCH; PANCREAS ISLET BETA CELL; PREVENTIVE MEDICINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TRIALNET CLINICAL RESEARCH;

EID: 57749176852     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1447.054     Document Type: Conference Paper

References (12)

1. Diabetes Prevention Trial-Type 1 Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346 : 1685 1691.
2. Diabetes Prevention Trial-Type 1 Diabetes Study Group. 2005. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Care 28 : 1068 1076.
3. Feutren, G., L. Papoz, R. Assan, et al., for the Cyclosporin/Diabetes French Study Group. 1986. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet ii : 119 124.
4. The Canadian-European Randomized Control Trial Group. 1988. Cyclosporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 37 : 1574 1582.
5. Skyler, J.S. & A. Rabinovitch, Miami Cyclosporine Diabetes Study Group. 1992. Cyclosporine in recent onset type 1 diabetes mellitus: effects on islet beta cell function. J. Diabetes Complications 6 : 77 88.
6. Shoda, L.K., D.L. Young, S. Ramanujan, et al. 2005. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23 : 115 126.
7. Request for Applications - Type 1 Diabetes TrialNet. http://grants.nih. gov/grants/guide/rfa-files/RFA-DK-01-003.html and http://grants.nih.gov/grants/ guide/rfa-files/RFA-DK-01-004.html.
8. Diabetes Control and Complications Trial Research Group. 1998. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann. Intern. Med. 128 : 517 523.
9. Steffes, M.W., S. Sibley, M. Jackson & W. Thomas. 2003. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26 : 832 836.
10. Incidence of Diabetes in the United States. http://www.cdc.gov/diabetes/ projects/cda2.htm.
11. Bluestone, J.A. & J.B. Matthews. 2000. The immune tolerance network-an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin. Immunol. 96 : 171 173.
12. Rich, S.S., P. Concannon, H. Erlich, et al. 2006. The type 1 diabetes genetics consortium. Ann. N. Y. Acad. Sci. 1079 : 1 8.